ADVANCED TREATMENTS IN THE REAL-LIFE OF COAGULATION AND RED CELLS RARE DISORDERS

Rare hematological diseases, while individually uncommon, collectively impact millions of lives worldwide. These conditions present significant challenges in terms of early diagnosis, treatment accessibility, and appropriate and effective patient communication. Overcoming these barriers requires a multidisciplinary international network aimed at establishing a common framework for corrective actions.
The rapid evolution of treatment options for rare hematological diseases necessitates ongoing education for healthcare professionals. This event focuses on several key areas where recent progress has been made, including:
⬝ Hemophilia: The program will explore real-world data on current hemophilia treatments and prophylaxis, including the latest international consensus recommendations. This is crucial for optimizing patient outcomes and ensuring consistent standards of care
⬝ Thalassemia and MDS: The event will address the real-life experience with luspatercept, a novel therapeutic agent, in the management of these challenging conditions. Sharing real-world data is essential for understanding the drug's effectiveness and safety profile in diverse patient populations
⬝ PK Deficiency, Thalassemia, and SCD: The program will highlight the role of mitapivat and etavopivat in these distinct diseases, providing a unique opportunity to compare and contrast its application across different rare hematological conditions. This comparative approach will enhance participants' understanding of targeted therapies
⬝ PTT: this is a real hematological emergency and difficulty in diagnosis and appropriate treatment recommendations in the “real-life” are so far to be empowered
⬝ PNH: the patients with this very rare hematological disease (1/1.000.000 inhabitants) now are living with the possibility of having different treatments. However, appropriate information and costs of these innovative treatments may become barriers for their use
⬝ GENE THERAPY: is now at the “the patient’s bedside” in some European countries. The meeting will address data from real-life in UK
⬝ AI: Artificial Intelligence may change our approach in collecting data of patients with rare hematological diseases.
This educational will address the possible use of a new AI tool to collect in more appropriate and faster way clinical data for randomized clinical trials.

6 settembre 2025 
DIRETTA WEBINAR dalle ore 9.00

È OBBLIGATORIA LA PRESENZA PER TUTTA LA DURATA DELLA TRASMISSIONE PER PROCEDERE ALLA PARTE ECM PREVISTA 
LA VISIONE DELLA REGISTRAZIONE NON SOSTITUISCE L'OBBLIGATORIETÀ DI PRESENZA ALLA DIRETTA

Al termine ogni partecipante dovrà sostenere un test di valutazione e compilare il modulo di qualità percepita attraverso la piattaforma
PASSAGGIO OBBLIGATORIO PER CONSEGUIRE I CREDITI ECM PREVISTI
Test e modulo si dovranno compilare entro il 09/09/2025
Attenzione: 

• numero massimo di tentativi a diposizione: 5
• soglia di superamento: 75% delle risposte corrette
  
  

IL PROGRAMMA È DISPONIBILE CLICCANDO Locandina IN ALTO PAGINA O Allegati A FONDO PAGINA

Per la fruizione della diretta sarà necessario installare il programma gratuito ZOOM, Potete effettuare il download del programma, e le relative istruzioni di installazione su https://zoom.us/download 

Questionario a risposta multipla e doppia randomizzazione da compilare tramite la piattaforma entro il 09/09/2025

Attenzione: 

• numero massimo di tentativi a diposizione: 5
• soglia di superamento: 75% delle risposte corrette